We are live on ! Find out more
VP

venBio Partners Portfolio holdings

AUM $519M
1-Year Est. Return 339.42%
This Fund
S&P 500
This Quarter Est. Return
-10.91%
1 Year Est. Return
+339.42%
3 Year Est. Return
+563.8%
5 Year Est. Return
+1,003.88%
10 Year Est. Return
–
AUM
$451M
AUM Growth
-$104M
Cap. Flow
-$8.13M
Cap. Flow %
-1.8%
Top 10 Hldgs %
100%
Holding
10
New
1
Increased
–
Reduced
1
Closed
–

Top Buys

Rank Stock Value
1
CINC
CinCor Pharma, Inc. Common Stock
CINC
+$40.6M

Top Sells

Rank Stock Value
1
HRMY icon
Harmony Biosciences
HRMY
+$48.8M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALXO icon
1
ALX Oncology
ALXO
$277M
$164M 36.34%
9,699,925
– –
HRMY icon
2
Harmony Biosciences
HRMY
$2.28B
$75.1M 16.66%
1,544,484
-1,195,927
-44% -$48.8M
VTYX
3
DELISTED
Ventyx Biosciences
VTYX
$68M 15.08%
5,011,536
– –
PHVS icon
4
Pharvaris
PHVS
$2.48B
$41.8M 9.26%
2,303,310
– –
CINC
5
DELISTED
CinCor Pharma, Inc. Common Stock
CINC
$34.7M 7.7%
+1,980,706
New +$40.6M
AKRO
6
DELISTED
Akero Therapeutics
AKRO
$30.8M 6.83%
2,171,664
– –
IMPL
7
DELISTED
Impel Pharmaceuticals Inc. Common Stock
IMPL
$17.6M 3.9%
2,759,791
– –
CMPI
8
DELISTED
Checkmate Pharmaceuticals, Inc. Common Stock
CMPI
$11.7M 2.6%
3,673,374
– –
ELEV
9
DELISTED
Elevation Oncology
ELEV
$6.57M 1.46%
2,608,167
– –
VRNA
10
DELISTED
Verona Pharma
VRNA
$808K 0.18%
161,897
– –

Similar funds

CFA
Churchill Financial Advisors Louisville, Kentucky $519M AUM
CFG
Compton Financial Group Towson, Maryland $519M AUM 14.76% 1-Year Est. Return
MWM
Mindset Wealth Management Indianapolis, Indiana $519M AUM 46.03% 1-Year Est. Return
SWM
Scissortail Wealth Management Tulsa, Oklahoma $520M AUM 21.73% 1-Year Est. Return
WS
Wendel SE Paris $519M AUM 48.2% 1-Year Est. Return
GS
Gagnon Securities New York $519M AUM 44.91% 1-Year Est. Return
MWC
MBM Wealth Consultants Chesterfield, Missouri $519M AUM 16.88% 1-Year Est. Return
PDIP
Palo Duro Investment Partners Chicago, Illinois $518M AUM 22.62% 1-Year Est. Return

venBio Partners's Q1 2022 Portfolio in Review

As of Q1 2022, venBio Partners held 10 positions worth $451M, down 19% from $555M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

venBio Partners's Q1 2022 filing shows 1 new and 1 reduced positions. Its largest new stake was CinCor Pharma, Inc. Common Stock: 1,980,706 shares worth $34.7M. The largest sale was Harmony Biosciences, an estimated $48.8M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • venBio Partners's largest Q1 2022 buy was CinCor Pharma, Inc. Common Stock: 1,980,706 shares worth $34.7M.
  • venBio Partners's biggest Q1 2022 reduction was Harmony Biosciences, cutting an estimated $48.8M.
  • venBio Partners's ten largest holdings make up 100% of its $451M portfolio in Q1 2022.
  • venBio Partners opened 1 new position and closed 0 in Q1 2022.
  • venBio Partners's portfolio value fell 19% quarter-over-quarter to $451M.

Based on venBio Partners's 13F filing for Q1 2022, filed 16 May 2022.